PCM
ALT icon

Prelude Capital Management’s Altimmune ALT Stock Holding History

Prelude Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,600
Closed -$32.8K – 1112
2023
Q3 		$32.8K Buy
+12,600
New +$36.1K ﹤0.01% 1061

Other funds holding ALT

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return

Prelude Capital Management's ALT Position: Q4 2023 in Review

Prelude Capital Management sold out of Altimmune (ALT) in Q4 2023, closing a stake of 12,600 shares — an estimated $32.8K sold.

Prelude Capital Management first reported a position in ALT in Q3 2023 and held it in 1 quarter. The position peaked at $32.8K in Q3 2023. 143 funds tracked by Wall St. Rank hold ALT as of Q4 2023.

  • Prelude Capital Management reported no remaining Altimmune position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 12,600 Altimmune shares in Q4 2023, an estimated $32.8K.
  • Prelude Capital Management first reported a position in Altimmune in Q3 2023 and held it in 1 quarter.
  • Prelude Capital Management's Altimmune position peaked at $32.8K in Q3 2023.
  • 143 funds tracked by Wall St. Rank held Altimmune as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.